Response to pneumococcal vaccination in multiple myeloma.
Adult
Aged
Antibodies, Bacterial
/ immunology
B-Lymphocytes
/ immunology
Enzyme-Linked Immunosorbent Assay
Female
Humans
Immunologic Memory
Male
Middle Aged
Multiple Myeloma
/ complications
Outcome Assessment, Health Care
Pneumococcal Infections
/ etiology
Pneumococcal Vaccines
/ administration & dosage
Vaccination
ELISA test
multiple myeloma
pneumococcal vaccination
prime boost
serological response
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
05
12
2018
revised:
24
04
2019
accepted:
02
05
2019
pubmed:
31
5
2019
medline:
4
8
2020
entrez:
31
5
2019
Statut:
ppublish
Résumé
Streptococcus pneumoniae infection causes morbidity and mortality in multiple myeloma patients. Pneumococcal vaccination is commonly given to immunocompromised myeloma patients; however response data are sparse. Here, we present longitudinal response data to pneumococcal vaccination in multiple myeloma patients. Twenty-eight multiple myeloma patients were included, 25 of whom were newly diagnosed. All the patients received two vaccines Prevnar13® and Pneumo23®. Serotype-specific IgG was measured by ELISA for all 23 vaccine serotypes at baseline, and then sequentially at different time points postvaccination until treatment ended. Response to vaccination is available for 20 patients. The primary endpoint was the incidence rate of patients who obtained an isotype response serum concentration after vaccination. Secondary endpoints included detailed isotype increase, time to first increase, further assessment of a decreased anti-pneumococcal serum concentrations following treatment including autologous stem cell transplantation (ASCT), rate of infection with a special attention to pneumococcal infection. The median age was 66 years and the male to female ratio was 0.6. Anti-pneumococcal capsular polysaccharide (anti-PCP23) IgG, IgG2, IgA, and IgM responses were detected within 1 week postvaccination. Response to at least one subtype of antibody was obtained in 85% (n = 17) of patients, for at least two subtypes in 65% (n = 13), for at least three subtypes in 55% (n = 11), and 2 patients responded to all four subtypes. The median increase in the concentration of anti-PCP23 isotypes was threefold following vaccination, with the highest increase observed when Pneumo23® was given more than 30 days after Prevnar13®. The anti-pneumococcal geometric mean concentration decreased significantly for all subtypes over time independently of treatment approaches. Myeloma has the ability to demonstrate a response to pneumococcal vaccine, independently of preexisting hypogammaglobulinemia and possibly of treatment-induced immunodepression. We also observed a drop in the serum response overtime and following autologous transplantation. Further studies in larger sample are needed to understand the benefit of vaccination strategies in these patients.
Sections du résumé
BACKGROUND
Streptococcus pneumoniae infection causes morbidity and mortality in multiple myeloma patients. Pneumococcal vaccination is commonly given to immunocompromised myeloma patients; however response data are sparse. Here, we present longitudinal response data to pneumococcal vaccination in multiple myeloma patients.
METHOD
Twenty-eight multiple myeloma patients were included, 25 of whom were newly diagnosed. All the patients received two vaccines Prevnar13® and Pneumo23®. Serotype-specific IgG was measured by ELISA for all 23 vaccine serotypes at baseline, and then sequentially at different time points postvaccination until treatment ended. Response to vaccination is available for 20 patients. The primary endpoint was the incidence rate of patients who obtained an isotype response serum concentration after vaccination. Secondary endpoints included detailed isotype increase, time to first increase, further assessment of a decreased anti-pneumococcal serum concentrations following treatment including autologous stem cell transplantation (ASCT), rate of infection with a special attention to pneumococcal infection.
RESULTS
The median age was 66 years and the male to female ratio was 0.6. Anti-pneumococcal capsular polysaccharide (anti-PCP23) IgG, IgG2, IgA, and IgM responses were detected within 1 week postvaccination. Response to at least one subtype of antibody was obtained in 85% (n = 17) of patients, for at least two subtypes in 65% (n = 13), for at least three subtypes in 55% (n = 11), and 2 patients responded to all four subtypes. The median increase in the concentration of anti-PCP23 isotypes was threefold following vaccination, with the highest increase observed when Pneumo23® was given more than 30 days after Prevnar13®. The anti-pneumococcal geometric mean concentration decreased significantly for all subtypes over time independently of treatment approaches.
CONCLUSION
Myeloma has the ability to demonstrate a response to pneumococcal vaccine, independently of preexisting hypogammaglobulinemia and possibly of treatment-induced immunodepression. We also observed a drop in the serum response overtime and following autologous transplantation. Further studies in larger sample are needed to understand the benefit of vaccination strategies in these patients.
Identifiants
pubmed: 31145552
doi: 10.1002/cam4.2253
pmc: PMC6639194
doi:
Substances chimiques
Antibodies, Bacterial
0
Pneumococcal Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3822-3830Informations de copyright
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Exp Hematol. 2001 Sep;29(9):1076-81
pubmed: 11532348
Ann Intern Med. 1982 Jan;96(1):47-50
pubmed: 6976144
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
J Clin Immunol. 2013 May;33(4):838-46
pubmed: 23274802
Pract Lab Med. 2016 Feb 24;5:1-5
pubmed: 28856197
J Clin Oncol. 2005 Dec 20;23(36):9219-26
pubmed: 16275935
Blood Rev. 2014 Mar;28(2):75-86
pubmed: 24582081
J Clin Pathol. 1995 Mar;48(3):260-6
pubmed: 7730490
J Clin Microbiol. 1995 Oct;33(10):2759-62
pubmed: 8567920
Clin Exp Immunol. 2001 Aug;125(2):190-7
pubmed: 11529908
Clin Microbiol Rev. 2015 Jul;28(3):871-99
pubmed: 26085553
J Clin Oncol. 2005 May 20;23(15):3412-20
pubmed: 15809451
Mediterr J Hematol Infect Dis. 2016 Sep 01;8(1):e2016044
pubmed: 27648207
Vaccine. 2012 Jun 22;30(30):4435-44
pubmed: 22542818
Cancer Med. 2019 Jul;8(8):3822-3830
pubmed: 31145552
APMIS. 2012 Nov;120(11):935-40
pubmed: 23009118
Haematologica. 2015 Jan;100(1):107-13
pubmed: 25344526
Br J Cancer. 2000 Apr;82(7):1261-5
pubmed: 10755398
Haematologica. 2003 Sep;88(9):1022-8
pubmed: 12969810
Vaccine. 1999 Apr 9;17(15-16):1889-97
pubmed: 10217586
Clin Infect Dis. 2008 Apr 1;46(7):1015-23
pubmed: 18444818
Med Microbiol Immunol. 2013 Aug;202(4):285-94
pubmed: 23529214
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Clin Vaccine Immunol. 2011 Jun;18(6):969-77
pubmed: 21508164
Am J Med. 1981 Dec;71(6):935-40
pubmed: 7315855
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224